Skip to content
Peptide research

Eloralintide

Also known as LY3841136
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

Eloralintide is an investigational long-acting amylin receptor agonist being studied for weight loss, alone and in combination with tirzepatide. The weight-loss effect is well supported, but preferential fat loss, GI tolerability, and GLP-1 synergy claims rest on weak evidence. Nausea affects up to two-thirds of patients at higher doses, and safety data run only to 48 weeks, with none in pregnancy or children. It is not FDA-approved.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Significant dose-dependent weight loss

    High

    48-week Phase 2 RCT showed dose-dependent weight loss, up to about 20%.

  • Preferential fat mass reduction

    Low

    A human Phase 2 DXA substudy found that most lost mass was fat. It did not establish the 80–91% preclinical figure or superiority over other treatments.

  • Favorable GI tolerability

    Low

    Phase 1 data suggested mild GI effects, but Phase 2 nausea reached up to 64%.

Evidence limits

Evidence Level
Phase 2 (Lancet RCT, n=263)

Phase 1 (n=48 SAD, n=100 MAD) and Phase 2 (n=263, 48-week RCT published in The Lancet) demonstrate dose-dependent weight loss up to 20% with favorable tolerability. Phase 3 ENLIGHTEN program initiated late 2025 across 171 global sites.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    No approved eloralintide contraindication list or boxed warning exists. Eloralintide is a selective amylin agonist; an established GLP-1 thyroid-tumor class warning should not be assigned to it. Trial eligibility must follow the relevant protocol.

  • History of pancreatitis

    High

    A history of pancreatitis was an exclusion criterion in the Phase 2 trial. This is a trial precaution, not an established incretin-class requirement for eloralintide.

General cautions

  • Pregnancy

    Absolute

    Investigational — no reproductive safety data.

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Nausea: dose-dependent, from 11% at the lowest to 64% at the highest Phase 2 dose, vs 14% placebo

    High
  • Fatigue: reported in 0-46% of participants across dose groups vs 12% placebo

    Moderate
  • Decreased appetite: 19% in Phase 1 MAD study

    Low
  • Headache: 12% in Phase 1 MAD study

    Low
  • GI effects: diarrhea (10%), vomiting (4%) in Phase 1

    Moderate
  • Long-term safety unknown — only 48-week data available from Phase 2

    High
  • Injection site reactions possible (subcutaneous administration)

    Low
  • Contraindication data not yet fully established (investigational drug)

    High
  • Not studied in pregnancy, lactation, or pediatric populations

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.